Brokerages Expect ContraFect Corporation (CFRX) Will Post Earnings of -$0.10 Per Share
Equities analysts predict that ContraFect Corporation (NASDAQ:CFRX) will report ($0.10) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for ContraFect’s earnings, with the highest EPS estimate coming in at ($0.09) and the lowest estimate coming in at ($0.10). ContraFect posted earnings per share of ($0.15) during the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The company is expected to announce its next quarterly earnings report on Wednesday, March 21st.
According to Zacks, analysts expect that ContraFect will report full-year earnings of ($0.33) per share for the current year, with EPS estimates ranging from ($0.33) to ($0.32). For the next year, analysts anticipate that the firm will report earnings of ($0.40) per share, with EPS estimates ranging from ($0.45) to ($0.35). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover ContraFect.
ContraFect (NASDAQ:CFRX) opened at $0.89 on Thursday. ContraFect has a twelve month low of $0.80 and a twelve month high of $2.50.
ILLEGAL ACTIVITY WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/07/brokerages-expect-contrafect-corporation-cfrx-will-post-earnings-of-0-10-per-share.html.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with MarketBeat.com's FREE daily email newsletter.